GLMD Galmed Pharmaceuticals Ltd
3,435
$0.42
$0.0224
(5.63%)
| Watchers | 3,435 |
| 52-Wk Low | $0.26 |
| 52-Wk High | $5.63 |
| Market Cap | $2.43M |
| Volume | 53,471.00 |
| 52-Wk High | $5.63 |
| 52-Wk Low | $0.26 |
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023PR Newswire • about 2 months ago
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended...
Share to Feed
StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD - Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the...
Equities research analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD Get Free Report) in a research note issued on Saturday. The firm set a...
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis Galmed Announces Grant of New Patent for the...
StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD Free Report) in a research report sent to investors on Thursday. The firm issued a sell rating on the...
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD Get Free Report) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average...
StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD Free Report) in a research note published on Saturday morning. The firm issued a sell rating on the...
StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD Get Free Report) in a report released on Friday. The brokerage set a sell rating on the...